Publicaciones en las que colabora con Benedicto Crespo Facorro (50)

2022

  1. Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort

    Psychological Medicine, Vol. 52, Núm. 4, pp. 770-779

2019

  1. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

    Translational Psychiatry, Vol. 9, Núm. 1

  2. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 92-105

  3. Verbal memory and voxel based morphometry in first episode non-Affective psychosis: A process oriented approach

    Neuropsychology, Vol. 33, Núm. 4, pp. 568-580

2018

  1. Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders

    Biochemical Pharmacology, Vol. 157, pp. 258-265

2016

  1. Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 266, Núm. 7, pp. 619-628

  2. Evidence for trait related theory of mind impairment in first episode psychosis patients and its relationship with processing speed: A 3 year follow-up study

    Frontiers in Psychology, Vol. 7, Núm. MAY

  3. Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis

    Brain Imaging and Behavior, Vol. 10, Núm. 3, pp. 629-635

2015

  1. Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis

    Cognitive Neuropsychiatry, Vol. 20, Núm. 2, pp. 144-156

  2. No progression of the alterations in the cortical thickness of individuals with schizophrenia-spectrum disorder: A three-year longitudinal magnetic resonance imaging study of first-episode patients

    Psychological Medicine, Vol. 45, Núm. 13, pp. 2861-2871

2014

  1. Lack of insight 3 years after first-episode psychosis: An unchangeable illness trait determined from first presentation?

    Schizophrenia Research, Vol. 157, Núm. 1-3, pp. 271-277

  2. No sex differences in neuropsychological performance in first episode psychosis patients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 48, pp. 149-154

2013

  1. Course of cognitive deficits in first episode of non-affective psychosis: A 3-year follow-up study

    Schizophrenia Research, Vol. 150, Núm. 1, pp. 121-128

  2. Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: A randomized comparison of haloperidol, olanzapine, and risperidone

    Psychopharmacology, Vol. 227, Núm. 4, pp. 615-625

  3. Predictors of neurocognitive impairment at 3years after a first episode non-affective psychosis

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 43, pp. 23-28

2012

  1. Homocysteine and cognition in first-episode psychosis patients

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 262, Núm. 7, pp. 557-564

  2. Identifying attentional deficits in people with first-episode psychosis with the Scale for the Assessment of Negative Symptoms attention subscale: Is it possible?

    Comprehensive Psychiatry, Vol. 53, Núm. 6, pp. 701-705

2011

  1. A digit symbol coding task as a screening instrument for cognitive impairment in first-episode psychosis

    Archives of Clinical Neuropsychology, Vol. 26, Núm. 1, pp. 48-58

  2. Global and regional cortical thinning in first-episode psychosis patients: Relationships with clinical and cognitive features

    Psychological Medicine, Vol. 41, Núm. 7, pp. 1449-1460

  3. Insight dimensions in first-episode psychosis patients: Clinical, cognitive, pre-morbid and socio-demographic correlates

    Early Intervention in Psychiatry, Vol. 5, Núm. 2, pp. 140-149